HPV vaccine

HPV vaccine
source
Type	Recombinant vaccine
Target	Human papillomavirus
Tradenames	Gardasil, Cervarix
Pregnancy AU	B2
Routes of administration	Intramuscular injection
ATCCode prefix	J07BM
ATCCode suffix	01, 02
Legal AU	S4
Legal CA	Rx-only
Legal UK	POM
Legal US	Rx-only
Legal EU	Rx-only
Legal status	Rx-only
CAS number	392678-63-0
DrugBank	BTD00090
UNII	8V5N018A0F
KEGG	D08917

HPV vaccine. It is an immunization designed to provide protection against infection by certain strains of the human papillomavirus, a group of more than 200 related viruses. The primary goal is to prevent cancers and other diseases caused by these viral infections, most notably cervical cancer, but also cancers of the vulva, vagina, anus, penis, and oropharynx, as well as genital warts. The development and widespread implementation of these vaccines represent a major advance in preventive medicine and public health, with the potential to significantly reduce the global burden of HPV-associated diseases.

Medical uses

The primary medical use is the prevention of precancerous lesions and cancers caused by targeted HPV types. Major global health organizations, including the World Health Organization and the Centers for Disease Control and Prevention, recommend routine vaccination for adolescents, typically starting at age 9 to 14. It is also recommended for certain older age groups who were not vaccinated earlier. The Advisory Committee on Immunization Practices provides specific guidance for use in the United States, while the National Health Service oversees its program in the United Kingdom. Vaccination is a key component of comprehensive cervical cancer control strategies, alongside Pap smear screening programs advocated by bodies like the American Cancer Society.

Types

Several prophylactic vaccines have been developed using virus-like particle technology. The first widely licensed vaccine was Gardasil, developed by Merck & Co. and approved by the Food and Drug Administration in 2006; it targets HPV types 6, 11, 16, and 18. Cervarix, produced by GlaxoSmithKline, is a bivalent vaccine protecting against types 16 and 18. Later, Merck & Co. introduced Gardasil 9, a nonavalent vaccine that protects against nine HPV types, which received FDA approval in 2014. These vaccines do not contain live virus but are composed of recombinant DNA-derived major capsid protein L1 from the respective HPV types.

Efficacy and safety

Clinical trials, such as those reviewed by the FDA and the European Medicines Agency, have demonstrated high efficacy in preventing persistent infection and disease caused by the vaccine-targeted types in individuals not previously exposed. Long-term follow-up studies, including work by researchers at the National Cancer Institute, indicate protection lasts for at least a decade. Safety is continuously monitored by systems like the Vaccine Adverse Event Reporting System and the Global Advisory Committee on Vaccine Safety. The most common side effects are minor, such as pain at the injection site; serious adverse events are rare. Organizations like the American Academy of Pediatrics strongly affirm its safety profile.

History and development

The foundational scientific work was pioneered by researchers including Harald zur Hausen of the German Cancer Research Center, who discovered the link between HPV and cervical cancer, for which he received the Nobel Prize in Physiology or Medicine in 2008. Key technological development of the virus-like particle vaccine was achieved by teams at the National Institutes of Health, the University of Queensland, and Georgetown University. The PATH organization has been instrumental in facilitating access in low-resource countries. Landmark approvals began with Gardasil in 2006, following large-scale trials like the FUTURE II study, marking a new era in cancer prevention.

Society and culture

The introduction sparked significant public discourse and varying levels of acceptance across different societies. Uptake has been influenced by factors including healthcare infrastructure, cost, and cultural attitudes toward vaccination and sexual health. Some opposition has been voiced by groups like the People's Medical Society, often related to misconceptions about safety or effects on adolescent behavior. Many countries have implemented national immunization programs, such as those in Australia and the United Kingdom, which have led to dramatic reductions in HPV prevalence and genital warts. The Gavi, the Vaccine Alliance works to improve access in the world's poorest countries, aiming to reduce global health inequities.

Category:Vaccines Category:Preventive healthcare